BRAF and melanoma: We also found that the combination was effective in melanoma cells carrying either BRAF or NRAS activating mutations, since A375, 1205Lu, and WM239a lines each have BRAFV600 mutations, while WM852c and SBCL2 lines have NRASQ61 mutations.